All In Biotech

Drug Trial Radar · NCT04656964

Comparison Between Remimazolam Tosilate and Midazolam in Elderly Patients Undergoing Gastrointestinal Endoscopy

The Safety and Effectiveness of Remimazolam Tosilate Versus Midazolam in Elderly Patients Undergoing Gastrointestinal Endoscopy: A Multicenter ,Prospective, Double-Blinded, Randomized Controlled Study

Last checked: Nov 20, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Apr 1, 2021

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Peking University People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Emergency General Hospital; Fenyang Hospital Affiliated to Shanxi Medical University
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Midazolam is a commonly used drug in gastrointestinal endoscopy due to the good cardiovascular stability and mild respiratory depression for elderly patients. However, there is the concern about the the longer and less predictable recovery or the potential for repeat sedation when the active metabolite becomes bioavailable. Remimazolam Tosilate is an innovative benzodiazepine with better sedation effect and less recovery or resedation issues than midazolam, which possibly make the drug more suitable in elderly patients. We aim to clarify whether remimazolam tosilate is better than midazolam in elderly patients undergoing gastrointestinal endoscopy.

Conditions

  • Elderly Patients
  • Gastrointestinal Endoscopy
  • Midazolam
  • Remimazolam

Interventions

  • remimazolam tosilate groupDrug

    Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).

  • Midazolam groupDrug

    Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recovery time after operationTime frame: Day 0

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.